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Abstract
In Sweden, snu (locally known as snus), was introduced since the year 1637. Presently, Sweden has the highest per capita con-
sumption and sale figures of snu in the world, and the habit is becoming increasingly popular. Snus is manufactured into a dry
form used in the nasal cavity and a moist form used in the oral cavity. Snus manufactured for oral use is a moist ground tobacco of
Dark Kentucky or Virginia species mixed with an aqueous solution of water and other blending ingredients. This form of snu is
found in two types: (1) loose and (2) portion-bag-packed. These are the most widely used. The loose moist form (1–2 g a quid) is the
most popular type consumed by 73% of the males, followed by the portion-bag-packed form (0.5–1 g a quid), consumed by 13% of
the males, while 14% of the males are mixed users. The majority of snus users place the quid in the vestibular area of the upper lip,
and the prevalence among persons 15 years of age or older is 15.9% among males and 0.2% among females. The pH of snus has
declined from a previous range of 8–9 to a range of 7.8–8.5, moisture content ranges 35–60% and nicotine content is in the order of
5–11 mg/g dry wt tobacco-specific N-nitrosamines (TSNAs) in micrograms (N0-nitrosonornicotine: NNN 5–9; 4-(methyl-
nitrosamino)-1-(3-pyridyl)-1-butanone: NNK 1–2; N0-nitrosoanatabine: NAT 2–5). In the Sudan, snu, locally known as toombak,
was introduced approximately 400 years ago. It is always processed into a loose moist form, and its use is widespread in the
country. Tobacco used for manufacture of toombak is of the species Nicotiana rustica, and the fermented ground powder is mixed
with an aqueous solution of sodium bicarbonate. The resultant product is moist, with a strong aroma, highly addictive and its use is
widespread particularly among males. Its pH range is 8–11, moisture content ranges 6–60% and nicotine content is from 8 to 102
mg/g dry wt, and TSNAs contents in micrograms (NNN 420–1 550; NNK 620–7 870; NAT 20–290). Snus and toombak dippers
develop a clinically and histologically characteristic lesion at the site of dipping. Probably due to control of the TSNAs in snus, this
type of snu is associated with a lower risk of cancer of the oral cavity (relative risk: RR 5–6-fold), whereas the risk for cancer of
the oral cavity among toombak users was high (RR 7.3–73.0-fold). In conclusion, the two snu products significantly dier in many
aspects. Most notable dierences are tobacco species, fermentation and ageing, nicotine and TSNAs content, pH, expression of the
p53 tumour supressor gene, and keratin types 13, 14, and 19. It was, therefore, the object of the present study to highlight the oral
health hazards of toombak, and to compare it with snus regarding the aforementioned dierences. # 1998 Published by Elsevier
Science Ltd. All rights reserved.
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1. Introduction
Expert committees of the International Agency for
Research on Cancer reviewed epidemiological studies
from dierent countries who indulge in smokeless
tobacco use and concluded that ‘‘the use of snu can
cause cancer in humans, and that the use of chewing
tobacco may increase the risk for oral cancer develop-
ment’’ [1]. Snu is a term used to describe a wide variety
of products containing finely ground tobacco as a prin-
cipal constituent and other additives. Snu is either
inhaled to the nasal cavity or dipped in the oral cavity.
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Epidemiological and laboratory studies have docu-
mented that use of snu is associated with increased risk
for cancer of the oral cavity [1,2]. Snu contains a
number of carcinogens, principally the most abundant
ones, the tobacco-specific N-nitrosamines (TSNAs),
which have been shown to be potent carcinogens in
experimental animals [1–3]. In addition, snu contains
other carcinogens including aliphatic and aromatic
hydrocarbons, formaldehyde, ketones, alcohols, phe-
nols, amines, amides, alkaloids, metals, radioelements
(e.g. polonium-210, uranium-235 and -238) and poly-
aromatic hydrocarbons (PAHs) [1–3].
The use of snu is common world-wide, but more
common in the southern parts of United States, the
Scandinavian countries, southern parts of the Kingdom
of Saudi Arabia, southern African countries and the
Sudan in northeast Africa. Scandinavian snu (locally
called snus), has been used for centuries. In Denmark,
the habit of snus dipping is widely prevalent and the
quid is usually placed between the lower lip and the
alveolar process [4]. In Norway, the habit of snus
dipping is uncommon, but presently is increasing par-
ticularly among young individuals, and the quid is
placed under the upper lip [5,6]. In Sweden, the habit
of snus dipping is the oldest in Europe and dates back
to the year 1637. In Sweden, snus consumption
declined for several decades during the period 1920–69
[7], increased by 92% during the period 1970–92, and
currently is the only tobacco product with increasing
sale figures [7]. Snus product for oral use is moist with
a pH value in the range 7.8–8.5 [7], and many dier-
ent brands are commercially available [7,8]. However,
the majority of snus users prefer only one or two
brands [7,8]. The most popular way of practising the
habit is by placing the quid in the upper gingivolabial
sulcus [7,8]. Sweden has the highest per capita con-
sumption and sale figures of snu in the world [7,8].
In Africa, consumption of snu (locally called toom-
bak) is particularly high in the Sudan where it has
been used for over three centuries [9]. While cancer of
the oral cavity is low in Sweden despite widespread
use of snus [10], an increased risk for cancer of the
oral cavity has been documented among toombak
dippers in the Sudan [9].
1.1. Snus
Snus is manufactured from the Dark Kentucky or
Virginia tobacco with relatively a high nicotine con-
tent compared to cigarettes [8]. The tobacco is selected
according to the content of nicotine which may vary
considerably. Both soil and climate where the tobacco
is grown determine the quality of the product. The
tobacco is dried in air or in barns by heating the air
with open fires (dark-fired) [8]. The smoke aects
both the aroma of the tobacco and its chemical
composition [8]. After cutting and grinding of the
leaves, water and salt are added to the dry flour to
keep it fresh and thereafter the snus is heated at high
temperature and humidity. To produce various
brands, other ingredients are usually added. The pur-
pose of heating is to eradicate micro-organisms and
lower nitrate and subsequent nitrosamine formation
[7]. Processing of the Swedish snus is a data controlled
free-hands tobacco industrial process that involves
several modifications through the dierent stages of
processing. However, the exact composition of the
blending additives remains a commercial secret [8].
Finally, and after repeated shifts, the snus is refri-
gerated until ready for packing, in waxed cardboard
containers with plastic lids, and the product is then
stored at +4C [8].
Snus is primarily moist snu with pH values pre-
viously 8ÿ9 but presently 7.8ÿ8.5, and is produced in
various commercial brands [7,8]. Sweden has the highest
prevalence of use of snu in the European Union, with
21% of all males (900 000 persons) using moist snus [11].
Of the two forms, loose and portion-bag-packed snus,
73% of the males consume the loose form and 13%
consume the portion-bag-packed form and the remain-
ing 14% are mixed users [7,8]. The habit is practised by
taking a pinch of 1–2 g of loose snus or sachets of por-
tion-bag-packed of 1-g sachets, and place it in contact
with the oral mucosa behind the upper lip [7,8]. The
average snus dipper keeps the snus in the oral cavity for
approximately 11–14 h/day, and consumes almost 75 g
a week, corresponding to approximately 4 kg of snus a
year [7,8]. Epidemiological studies have shown that
changes of the oral mucosa and gingival margins are
less pronounced among users of portion-bag-packed
snus compared to users of loose snus who show
more pronounced gingival recessions which seem to be
irreversible [7].
1.2. N-nitrosamines
Snus leading brands were found to contain levels of
TSNAs ranging from 5.5 to 106 ppm [8]. Waxed card-
board snus containers were found to contain morpho-
line. Diusion of morpholine into snus and subsequent
N-nitrosation may result in formation of N-nitroso-
morpholines (NMOR), a potent experimental carcino-
gen [8]. On the other hand, snus portion bags wrapped
in aluminium foil have been reported to contain sig-
nificantly fewer quantities of volatile N-nitrosamines
(VNA) and N-nitrosodiethanolamine (NDELA) and
TSNAs [8], which demonstrates one possibility to
reduce deleterious substances in snus. The levels of
nicotine and TSNAs in snus have been reported during
the period 1980–90 (Table 1), and were found in the
range of 11.3–18.1 mg/g for nicotine, and 5.5–106 ppm
for TSNAs.
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1.3. Toombak
In the Sudan, nasal use of snu is found only in the
far southern parts of the country and only oral use
which is widespread is described. Toombak is a native
tobacco plant of the species Nicotiana rustica used for
manufacture of snu. Toombak is grown in silky or
sandy soils which receive heavier rainfalls in the north-
west of the Sudan. After the end of the rainy season
(September/October), toombak is planted during the
months November/December and never irrigated. Har-
vesting starts in the months February/March when the
leaves turn yellow and brownish spots start appearing
(called the smallpox stage). Harvested leaves are left in
the field for uniform drying, tied into bundles, mois-
tened with sprinkling of water and stored for fermenta-
tion for a couple of weeks at temperature ranging from
30 to 45C, during which bundles are separated for
uniform drying during the months April/May. Tobacco
leaves are ground and stored for a year for ageing [12].
Introduction of this tobacco plant to the Sudan was
attributed to a Koranic (Islamic) teacher, who came to
the Sudan either from Egypt, Timbuktu of Mali or
Morocco. It has also been suggested that toombak was
introduced to the Sudan from Turkey or Arabia.
Another popular name for toombak is Saute´, which
means sning of the product in the local language,
indicating nasal usage when it was first introduced. The
commercial names for toombak include, El-sanf (of high
quality), Wad Amari (accrediting the person who was
believed to have introduced it) and Sultan El-kaif (the
power to improve one’s state of mind) [12].
Processing of toombak for sale is usually carried out
manually in toombak shops by toombak vendors [12]. It
is performed by preparing four parts of a coarse powder
of dried toombak leaves in a bowl and in another the
concentrate of sodium bicarbonate is added gradually in
small amounts to the tobacco [12]. While adding the
solution, the product is mixed vigorously by both hands
and concurrently tested by sensation of the tips of the
fingers until it becomes moist and hardened. The output
is then transferred to special air-tight tin-containers
which are then covered firmly for about 2 h, thereafter
the product becomes ready for sale or use. Before buy-
ing, users generally ask for a bit to smell or taste, since
the aroma and taste decide the quality rank of the pro-
duct. Currently, toombak is sold in small plastic bags
each taking about 100 g. The toombak user carries
round or box-shaped tin cans in his pocket, named
hookah and is similar to plastic bags, though some
people use king-size ones. Hookah is still used by
some people, and it makes an indentation in the pocket
of a user, thus one can easily guess and identify a user.
This helps users to communicate with each other for
exchange of brand or request of a dip. A regular user
consumes an average of 10–20 dips per day, thus
requiring a steady supply of toombak.
1.4. Natron (sodium bicarbonate)
Natron or atron (sodium bicarbonate, also called
sodium hydrogen carbonate), is a mineral rock with the
chemical formula Na2H(CO3)2.2H2O. Its colour is grey
to yellowish white, and is of alkaline pH. There is no
information on either the history or reasons behind use
of atron as an additive to toombak. It may be used to
homogenise the leaves to a fine sticky form as atron is
used in the Sudan to homogenise vegetables during
cooking.
Atron, opposed to lime in other parts of the world, is
probably added to toombak for its alkaline eects. It has
been shown that at high pH (11.0–11.8) nicotine is
Table 1
Levelsa of nicotine and the tobacco-specific N-nitrosamines in snus and toombak
Sampleb Year Nicotine (mg/g) NNN (mg/g) NNK (mg/g) NAT (mg/g) NAB (mg/g) Reference
Snus
A(5) 1980–90 12.4–15.1 5.67–7.83 1.0–2.08 2.2–5.13c [19]
B(5) 1980–90 12.5–18.1 4.0–7.95 0.61–1.51 1.4–4.43c
C(5) 1980–90 11.3 5.24–8.94 1.40–1.85 2.4–5.50c
Toombak
A(5) 1990 32.2–102.4 830–3085 630–7870 66–290 40–2370 [15]
B(5) 1990 8.4–26.0 420–1550 1140–2790 30–140 60–210
C(4) 1990 16.5–22.8 490–960 1170–2270 20–80 20–220
D(4) 1990 17.9–40.6 850–1800 620–3830 50–130 90–230
E(2) 1990 26.4–26.6 780–970 1610–1680 20–40 80
I(5)d 1993 241–369 188–362 21–42 14–43 [51]
a All values are based on dry weight.
b Numbers in parentheses are numbers of samples analysed.
c NAT contains 5–10% NAB.
d Samples also contain 1.4–20.7 mg iso-NNAL, and up to 22.9 mg NNAL/g tobacco.
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completely protonated and its rate of absorption is
increased [13]. Studies of nass, a type of snu used in the
former USSR which contains lime and has high pH (11–
11.8), have shown that when the product is placed in the
mouth, nicotine reaches the central nervous system very
quickly [14]. Thus, pH value in tobacco products can
influence the absorption and thereby the extent of
pharmacological activity of nicotine [14]. Atron prob-
ably quickens absorption of nicotine from toombak to
the central nervous system.
1.5. The habit
Toombak can be bought from innumerable shops in
the market, and the product is advertised extensively at
points of sale where vendors tend to use commercial
names to attract buyers [12]. The habit of toombak dip-
ping is practised by taking a small portion from the bag
or hookah with the three fore-fingers, usually of the
right hand, putting it in the palm of the left hand, and
manipulating it by the thumb and middle fingers of the
right hand until it forms a ball called saa which is of
about 10 g in weight [12]. The saa is not chewed but
dipped and retained between gum and lip or cheeks or
floor of mouth, and sucked slowly for about 10–15 min.
Generally, men prefer dipping between the lower lip and
gum, while women prefer dipping between cheeks and
gum. The dipping continues for a period ranging from a
few minutes to several hours, until the saa becomes
bland. Men periodically spit the insoluble debris that is
freed from the bullous and the saliva which is secreted
during toombak use, whereas women retain the saa,
without spiting because of social unacceptability. The
mouth is usually rinsed with water after the quid is
removed. The toombak quid is sometimes retained in the
mouth during sleep [12].
1.6. N-nitrosamines
Using gas chromatography with thermal energy ana-
lysis, the TSNA types; N0-nitrosonornicotine (NNN), 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK),
N0-nitrosoanatabine (NAT) and N0-nitrosoanabasine
(NAB) were quantified in toombak and saliva of toom-
bak users [15,16]. Exceptionally high levels (mean;
range, mg/g toombak/dry wt) of NNN (1.13; 0.50–3.08),
NNK (2.31; 0.62–7.87; 31), NAT (0.08; 0.02–0.2) and
NAB (0.22; 0.02–2.37) were found (Table 1). Previously,
the highest levels of NNN and NNK in any oral tobacco
found were 0.154 and 0.014 mg/g dry wt, respectively
[17]. Two additional TSNAs, 4-(methylnitrosamino)-1-
(3-pyridyl)-1-butanol (NNAL) and 4-(methylnitrosam-
ino)-4-(3-pyridyl)-1-butanol (iso-NNAL) were found in
the saliva of toombak users for the first time and were
confirmed by gas chromatography mass spectrum [16].
Exposure to TSNAs has also been assessed by measuring
the content in the saliva of 21 toombak users, where nine
out of 10 subjects had detectable levels of TSNAs in
their saliva before dipping (total TSNAs: 0.01–1.0 mg/
ml). During toombak use, TSNAs concentrations have
reached g/ml levels (range: number of positive subjects)
for NNN (0.6–1.2, 12/12), NAT (0.6–6.7, 2/12), NAB
(0.05–1.9, 12/12), NNK (0.06–6.7, 8/12), NNAL (0.05–
3.3, 11/12) and iso-NNAL (0.07–0.4, 8/12). These high
levels of TSNAs found in toombak were partially
attributed to the use of tobacco Species, Nicotiana
rustica, fermentation of toombak at elevated tempera-
ture, prolonged storage, and contamination during
processing [18–20].
Levels of nicotine and TSNAs in snus and toombak
were previously compared [21]. Tables 1 and 2 show
quantitative data on nicotine and TSNAs in various
snus brands and saliva of snus dippers and compare that
with concentrations of nicotine and TSNAs in various
samples of toombak and saliva of toombak dippers.
These data clearly document that toombak contains
concentrations of TSNAs 100-fold higher than those
found in snus (Table 1). The level of NNN and NNK in
the saliva of toombak dippers is also significantly higher
than those found in the saliva of snus dippers (Table 2).
It has been estimated that more than 80% of the carci-
nogenic TSNAs are extracted from the toombak by sal-
iva and negative pressure during sucking of dipped
toombak quid [20]. The concentrations of TSNAs in the
saliva of toombak dippers exceeded their concentration
in a solution that produced mouth tumours in rats
swabbed with this solution twice daily [22]. Whereas
epidemiological studies suggest low incidence of oral
cancer in Sweden [10], both high relative frequencies of
oral cancer as well as increased risk of oral cancer
development among toombak dippers in the Sudan have
been reported [9,21]. These data strongly support the
widely held idea that the TSNAs NNN and NNK play
an important role in carcinogenicity of toombak.
1.7. Prevalence
Large-scale surveys from Sweden in comparison with
similar surveys from the Sudan have shown that snus is
increasingly used by young individuals whereas toombak
is increasingly used as persons get older. Use of snus by
young individuals in Sweden suggests an alternative to
smoking of cigarettes. Table 3 shows a large-scale sur-
vey in Sweden and its comparison with similar surveys
from the Sudan. An informative report on prevalence of
toombak use and cigarettes smoking in a random popu-
lation sample of 4535 (21 433 household members;
22.6% males, and 1.7% females), in the population
of age 4 years or older, in the Nile Province north of
Khartoum, Sudan, has been described [9]. Among indi-
viduals of age 18 years or older, the average prevalence
rate for use of toombak was found to be 34% in males
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compared to 2.5% in females [9]. Use of toombak has
ranged between 40 and 47% among males of 40 years of
age or older, while among adults in rural areas, 40%
of males were found to use toombak compared to 24%
found in urban areas [9]. Rural populations were found
to use home processed toombak whereas urban ones use
more vendor-processed toombak. However, both groups
follow a similar processing procedure [9].
Almost all snus-dippers in Sweden in the 15–65-year
age group are males, implying about 17% of the popu-
lation [8]. When stratified, prevalence of the habit
accounted for 19% for the age group 15–30 years, and
10% for the age group 65 years and above. Only 1% of
Swedish women used snus [8,23]. Among school chil-
dren aged 13–16 years, 11–15% of the boys, but none of
the girls used snus regularly [24,25]. There are regional
dierences in the habitual of use of snus in Sweden.
Accordingly, the habit is widely spread in the northern
part of the country where almost 25% of the male
population over 15 years use snus daily [23]. The habit is
also more common in rural areas (20%) and in small
towns (13%) than in larger towns (7%) [26]. It has been
reported that people with a high consumption of snus
smoked less (12 cigarettes/daily) than people with limited
snus habits. Of the male snus dippers, 43% did not smoke
at all, while 22% smoked occasionally and 35% were
regular smokers as well as snus dippers [8]. Recently, it
has been reported that about 21% of all males in Sweden
use moist snus regularly, implying 900 000 persons, of
which >500 000 use only smokeless tobacco and about
335 000 use both cigarettes and smokeless tobacco, and
only 8% of the users are women [11].
1.8. Oral cancer
The first study from Scandinavia on snus-associated
soft tissue changes was published in 1937 [27]. In that
report, among 496 men with cancer of the oral cavity,
pharynx, larynx and or oesophagus registered between
1930–36, 91% were daily snus users, and 70% of 68
cases of outer oral cavity cancers used snus. In another
case control study, it has been concluded that chewing
of tobacco is common among men, with the cases being
too small to suggest that it could be a risk factor. It has
been stated that, snus dipping in Sweden apparently
increases the risk of oral cancer at the site where snu is
placed five- to six-fold [28]. In addition, the role of the
Swedish snus alone or in combination with live HSV-1
as an aetiological factor in development of oral cancer
has been studied [29]. More recently, quite a number of
studies have been carried out in Sweden to elucidate a
possible risk of snus use and oral cancer [7,8,29–32].
Table 2
Levels of the tobacco-specific N-nitrosamines in the saliva of snus and toombak dippers
Product Year No. of
samples
TSNA (ng/ml saliva)
NNN NNK NATa NAB Reference
Snus 1988 4 3–140 nd–16 4–85 [52]
Toombak 1991 12b 582–21 000 63–6690 nd–471 46–1944 [16]
1993 6 14.8–105.7 20–135 2.3–20.4 2.6–14.2 [53]
nd, not detected.
a NAT contains 5–10% NAB.
b Saliva sample [12] contains 52–3272 ng NNAL/ml saliva.
Table 3
Prevalence of use of snus in Sweden and toombak in the Sudan
Survey Year Age (years) No. % Reference
Snus
University of Malmo¨ 1970–73 15 20 333 15.9 [39]
Toombak
University of Kartoum 1992 520 2868 41.6 [21]
Toombak
Toombak Research Centre and
Oral Cancer Campaign, Khartoum




54 11 068 23.0
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However, this has been supported by some studies [8,29]
and questioned by others [7,30–32]. According to dis-
agreement between the results of these studies and
others, the Swedish Board of Health and Welfare sym-
posium, held in September 1996, questioned the law
which orders the manufactures to label the snus product
with the text ‘‘Causes cancer’’, adopted after the IARC
statement [1]. Nevertheless, the IARC statement was
based on intense epidemiological as well as laboratory
findings identified from dierent populations. Thus, it is
clear that there is a need for further research into the
field before any further questioning of the IARC
statement.
Although a high relative frequency of oral cancer in
the Sudan has been observed since the years 1959 and
1963 [33,34], the earliest observation on the association
between oral cancer and use of toombak was reported in
1980 [35]. Much later, it was found that 81% (50/62) of
patients with oral squamous cell carcinoma (SCC) from
the Sudan used toombak [36]. Recently, abundant
information on toombak use and development of oral
cancer has been reported, and the cancer was frequently
found at the site where the toombak quid is placed
[9,12,15,16,21]. Studies of a similar nature from Saudi
Arabia have suggested the aetiological role of Shamma
for development of oral cancer [37,38]. So far, only one
case control study from the Sudan has quantified the
risk associated with use of toombak [12]. In that study,
the history of the use of toombak was compared in four
case groups including: (1) 375 with SCC of the lip, buc-
cal cavity and floor of mouth; (2) 271 with SCC of the
tongue, palate and maxillary sinus; (3) 204 with benign
neoplasms in the oral cavity and/or other sites of the
body; and (4) 2820 with no malignancy selected from
the general population [12]. The adjusted odds ratio
(OR) associated with toombak dipping for the first case
group (cancer of the lip, buccal and floor of mouth) in
comparison with the other hospital and general popu-
lation control groups was 7.3 and 3.9 (95% confidence
limits, 4.3–12.4 and 2.9–5.3), respectively, and among-
long term users of toombak, the OR was 73.0 for the
hospital controls (95% confidence limits, 9.8–542.2)
[12].
The clinical and histological features of snus-induced
lesions in Scandinavia have been the subject of several
studies [4,7,8,39]. The clinical characteristics of snus-
induced lesion at the site of quid placement have been
described as white or yellowish to brownish colour
changes, a wrinkled or folded surface and a clear
demarcation to diuse merging into surrounding nor-
mal mucosa [4,7,8,39]. A four-point scale of clinical
grading of these lesions has been introduced [39]. The
severity of the grade is correlated with increased con-
sumption (h/day/year). Two major histological patterns
of changes in the surface epithelium were recognised
[7,39]. The first pattern is increased epithelial thickness
with vacuolated cells. The second was frequent chevron
type changes and variable thickness with evidence of
keratinization. High daily use was associated with rela-
tively more pronounced epithelial changes [7]. It has
been concluded that tissue changes clinically as well as
histologically including presence of epithelial dysplasia
are reversible following cessation of the snus habit [7].
The clinical and histological features of toombak dip-
pers’ lesions have been described [40]. The character-
istics of the clinical and histological features of toombak
dippers’ lesions were found to be similar to those of
snus dippers’ lesions. This similarity is probably due to
high alkalinity of both products, although the previ-
ous high alkalinity pH (8–9) of snus has recently
reduced to 7.8–8.5 [7]. A positive correlation between
severity of the lesion and longer life-time duration (>10
years) but not daily frequency, of the habit of toombak
use was found [40]. However, increased severity of the
lesion in snus users, was found associated with both
daily and longer life-time duration of use [7]. Similar to
snus dipper’s lesion, increased epithelial thickness,
Parakeratosis, pale surface staining and chevron type
keratinization were observed in toombak dipper’s lesions,
but epithelial dysplasia was found to be low [40].
1.9. p53, keratins (Ks) and human papillomavirus
(HPV) infection
The p53 tumour suppressor gene encodes a nuclear
phospho-protein that plays an important role in cell
proliferation and direntiation [41,42]. The most com-
mon genetic alterations identified in human cancers are
mutations in the p53 tumour suppressor gene [42]. A
high frequency of p53 mutations has been observed in
tobacco-related cancers [43], including head and neck
[44]. Expression of p53 in premalignant oral lesions and
oral squamous cell carcinomas from Swedish and
Sudanese snu dippers, as well as in premalignant and
malignant oral lesions from non-snu dippers from the
Sudan, Sweden and Norway, have been investigated by
immunohistochemistry [45]. Only 2/15 fibro-epithelial
hyperplasia from snus dippers and 3/14 carcinomas
from toombak dippers expressed p53, whereas expres-
sion of p53 in carcinomas from non-dippers from the
Sudan, Sweden and Norway was found in 9/14, 39/60
and 28/41, respectively [45]. Although results of immu-
nohsitochemistry are not always conclusive, these find-
ings suggested that the low expression of p53 found in
toombak and snus-associated oral lesions may be due to
formation of the p53 protein to cytoplasmic complexes
with other proteins, mainly Ks and HPV proteins. In
another study, toombak dippers’ lesions (49 including 40
dysplastic), and snus dippers’ lesions (15 fibro-epithelial
hyperplasias) were examined by immunohistochemistry
for expression of K types 13, 14, and 19 and for
presence of HPV DNA by in situ hybridization [46].
A.M. Idris et al./Oral Oncology 34 (1998) 558–566 563
Moderate to intense expression of K13 and K14 was
seen in all toombak dippers’ lesions compared to mod-
erate to weak expression of K13 in 12/15 (80%) and
K14 10/15 (67%) in the snus dippers’ lesions [46]. K19
was expressed in the basal layer in 16/49 (33%) of the
toombak dippers’ lesions compared to no expression in
the snus dippers’ lesions [46]. All tissues were found
negative for HPV except two dysplastic toombak dip-
pers’ lesions. The low expression of these markers in
snus dippers’ lesions suggests dierences in the biologi-
cal eects of these products on oral tissues as well as a
lower rate of malignant transformation of snus dippers’
lesions [46]. Later, carcinomas from Sudanese (toombak
dippers/non-dippers), Swedish and Norwegian (non-
snu dippers) were examined for expression of K13,
K14 and K19 and HPV infection. For the oral carcino-
mas from toombak dippers, moderate to intense expres-
sion of K13 (71%; 10/14), K14 (86%; 12/14) and K19
(93%; 13/14) was found [47]. For the oral carcinomas
from non-snu dippers, weak to moderate expression of
K13 (64%; 47/74), K14 (43%; 32/74) and K19 (45%;
33/74) was found [47]. HPV DNA was not detected in
any of the carcinomas from the three countries [47]. The
study suggested that high levels of expression of the Ks
investigated in oral carcinomas from toombak dippers,
compared to those from non-toombak dippers is per-
haps due to dysregulation of keratinocyte proliferation
and maturation caused by damaging eects of toombak
[47]. Otherwise, it may explain the low level of p53
expression previously found in toombak-associated oral
carcinomas which is currently under investigation at the
gene level [45].
1.10. Other health eects
The increased popularity of toombak use in recent
years seems to be due to it satisfying some psychosocial,
pharmacological, economical and social demands.
Regarding the psychosocial demands, toombak helps to
alter mood, and ambiguously helps both concentration,
and relaxation and distraction that is provided by both
the intervals of preparation of the saa and the dipping.
The pharmacological eects are mainly attributed to
nicotine which is a powerful pharmacological agent that
changes the cardiovascular, neural, endocrine, and
muscle function and induces eects in the gastro-
intestinal tract [48]. The cardiovascular changes include
increased heart rate, blood pressure and decrease in skin
temperature due to vasoconstriction in the extremities
[48]. The neural eects in the brain and the peripheral
nervous system are associated with changes in electrical
cortical activity, i.e. induction of both stimulation and
relaxation [48]. In the gastrointestinal tract, nicotine
stimulates the parasympathetic autonomic ganglia and
brain stem, causing the release of pharmacologically
active substances which may produce nausea, vomiting
and occasionally diarrhoea [48]. Therefore, it is now
accepted that tobacco causes physical dependence,
addiction and habituation [48]. A case control study
from Sweden showed an odd ratio for myocardial
infarction of 0.89 (95% confidence interval 0.62–1.29) in
non-smokers who used snus daily [49]. On the other
hand, smokers showed a clear increase in risk (odds
ratio 1.87, 95% confidence interval 1.40–2.48), blood
pressure and serum cholesterol levels were found similar
in snus users and smokers among the controls. Another
study (cohort) revealed a relative risk for death from
cardiovascular disease of 1.4 (95% confidence interval
1.2–1.6) in snus users who had never smoked [50]. In
non-snus using smokers of >15 cigarettes/day, the cor-
responding relative risk was found to be 1.9 (1.7–2.2).
The results were unchanged when adjusted for cardio-
vascular risk factors, such as body mass index and
blood pressure. An excess risk was indicated in those
dying before 55 years of age in both snus users and
smokers [50]. Recently, it has been concluded that snus
use in Sweden involves as high exposure to nicotine as
smoking causes release of sympathoadrenergic stimuli
which may signify an elevated risk of cardiovascular
stress including higher heart rate and blood pressure
levels, thus influencing the risk of fatal cardiovascular
events [11]. In the Sudan, nicotine content estimated
from a toombak sample was found to be 32.2–102.4 mg/
g dry wt compared to 17.1–23.4 mg/g dry wt and 12.4–
15.1 mg/g dry wt of snu used in USA and Sweden,
respectively [21]. These data clearly document that
toombak contains a range of two- to five-fold higher
concentration of nicotine than does the commercial
snu manufactured in the United States and in Sweden.
Therefore, during dipping nicotine is extracted from
toombak and immediately deprotonated in the alkaline
media provided by the natron; thus its absorption to the
central nervous system is accelerated. These data sup-
port the conception that non-smoked tobacco product
is a highly addictive product and its self-administration
cannot be resisted.
In conclusion, despite snus and toombak both being
snu forms, the two products dier in many respects,
and on their biological impact. They dier in type of
tobacco species, ageing, fermentation, methods of pro-
cessing and manipulation, packaging, pH value, moist-
ure, nicotine, and nitrosamines content and the way the
habit is practised and age of predominant use. The
major dierences which are expected to have significant
biological consequences, particularly addiction and car-
cinogenesis, are pH and levels of the TSNAs.
Clearly, quantitative risk estimates on occurrence of
cancer among snus and toombak dippers in non-smokers
are needed. This research program will document the
role of snu, particularly snus and toombak, as an
inducer of cancer in humans and it will arm the
importance of nicotine, nor-nicotine, anatabine and
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anabasine defined N-nitrosamines in snu carcinogen-
esis. Such an intervention program will be useful for
populations at high risk in the Sudan, Sweden, the rest
of Europe and the USA which could also specifically
contribute to a reduction of toombak and snus use,
modification of the product or use of an alternative
product.
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